. 2009 May 27;16(7):969–977. doi: 10.1128/CVI.00068-09

TABLE 3.

Immune responses to PsA-TT and PsA/C by OPA assay

Vaccine group	OPA GMT (95% CI; n) by assay and time								No. of subjects with≥4-fold increase in titer between prevaccination and postvaccination/total no. of subjects (%) at time postvaccination
	CDC OPA				NIPH OPA				CDC OPA			NIPH OPA
	Prevaccination	Wk postvaccination			Prevaccination	Wk postvaccination			4 wks	24 wks	48 wks	4 wks	24 wks	48 wks
	Prevaccination	4	24	48	Prevaccination	4	24	48	4 wks	24 wks	48 wks	4 wks	24 wks	48 wks
PsA-TT	443 (232-845; 24)	2,656 (1,713-4,118; 24)^a	813 (571-1,156; 24)^b	271 (163-452; 24)^c^,^d	11 (6-20; 24)	50 (31-78; 24)^a^,^f	11 (6-20; 24)^b	10 (6-18; 24)^d^,^f	15/24 (63)	9/24 (38)	6/24 (25)	12/24 (50)	5/24 (21)	4/24 (17)
PsA/C	820 (526-1,277; 25)	2,165 (1,268-3,695; 25)^a	556 (350-883; 25)^b	147 (81-268; 25)^c^,^d^,^e	10 (6-15; 25)	22 (13-37; 25)^a^,^f	6 (4-9; 24)^b	5 (3-8; 25)^d^,^e^,^f	13/25 (52)	2/25 (8)	1/25 (4)	8/25 (32)	2/24 (8)	1/25 (4)

Significant rise between prevaccination and 4 weeks postvaccination (P < 0.001).

Significant decline from 4 weeks postvaccination to 24 weeks postvaccination (P < 0.001).

Significant decline from 24 weeks postvaccination to 48 weeks postvaccination (P < 0.001).

Significant decline from 4 weeks postvaccination to 48 weeks postvaccination (P < 0.001).

Significant decline between prevaccination and 48 weeks postvaccination (P < 0.01).

Significant difference between the two vaccine groups (P = 0.02).